JP2024075713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024075713A5 JP2024075713A5 JP2024046063A JP2024046063A JP2024075713A5 JP 2024075713 A5 JP2024075713 A5 JP 2024075713A5 JP 2024046063 A JP2024046063 A JP 2024046063A JP 2024046063 A JP2024046063 A JP 2024046063A JP 2024075713 A5 JP2024075713 A5 JP 2024075713A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- formulation according
- amino acid
- acid sequence
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380652P | 2016-08-29 | 2016-08-29 | |
| US62/380,652 | 2016-08-29 | ||
| PCT/US2017/049211 WO2018044948A1 (en) | 2016-08-29 | 2017-08-29 | Anti-cd3 antibody formulations |
| JP2019531579A JP7057360B2 (ja) | 2016-08-29 | 2017-08-29 | 抗－ｃｄ３抗体製剤 |
| JP2022063973A JP7461401B2 (ja) | 2016-08-29 | 2022-04-07 | 抗－ｃｄ３抗体製剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063973A Division JP7461401B2 (ja) | 2016-08-29 | 2022-04-07 | 抗－ｃｄ３抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024075713A JP2024075713A (ja) | 2024-06-04 |
| JP2024075713A5 true JP2024075713A5 (https=) | 2024-08-21 |
Family
ID=59858782
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531579A Active JP7057360B2 (ja) | 2016-08-29 | 2017-08-29 | 抗－ｃｄ３抗体製剤 |
| JP2022063973A Active JP7461401B2 (ja) | 2016-08-29 | 2022-04-07 | 抗－ｃｄ３抗体製剤 |
| JP2024046063A Pending JP2024075713A (ja) | 2016-08-29 | 2024-03-22 | 抗－ｃｄ３抗体製剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531579A Active JP7057360B2 (ja) | 2016-08-29 | 2017-08-29 | 抗－ｃｄ３抗体製剤 |
| JP2022063973A Active JP7461401B2 (ja) | 2016-08-29 | 2022-04-07 | 抗－ｃｄ３抗体製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10688186B2 (https=) |
| EP (2) | EP3504241B1 (https=) |
| JP (3) | JP7057360B2 (https=) |
| CN (2) | CN116617387A (https=) |
| AU (2) | AU2017319318B2 (https=) |
| CA (1) | CA3032596A1 (https=) |
| DK (1) | DK3504241T3 (https=) |
| ES (1) | ES2986900T3 (https=) |
| IL (2) | IL264502B2 (https=) |
| WO (1) | WO2018044948A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116617387A (zh) | 2016-08-29 | 2023-08-22 | 迪赞纳生命科学公开有限公司 | 抗cd3抗体制剂 |
| EP3634478A4 (en) * | 2017-06-06 | 2021-03-24 | The Brigham and Women's Hospital, Inc. | METHOD OF SUPPRESSION OF MICROGLIA ACTIVATION |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| US20220220202A1 (en) * | 2018-10-09 | 2022-07-14 | Monash University | Combination therapy for treatment and prevention of autoimmune and inflammatory diseases |
| US20220008533A1 (en) * | 2018-10-31 | 2022-01-13 | Tiziana Life Sciences Plc | Composition and methods of treating inflammatory and autoimmune diseases |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CA3148179A1 (en) | 2019-08-20 | 2021-02-25 | Bruce J. Mccreedy Jr. | Lymphodepletion dosing regimens for cellular immunotherapies |
| IL296276A (en) * | 2020-03-10 | 2022-11-01 | Tiziana Life Sciences Plc | Compositions of il-6/il-6r antibodies and methods of use thereof |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| CN116406274B (zh) * | 2020-07-30 | 2026-02-17 | 迪赞纳生命科学公开有限公司 | 用于治疗冠状病毒的cd3抗体 |
| EP4188543A1 (en) * | 2020-07-31 | 2023-06-07 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding protein |
| US20220332822A1 (en) * | 2021-04-16 | 2022-10-20 | Tiziana Life Sciences Plc | Subcutaneous administration of antibodies for the treatment of disease |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| WO2023218100A1 (en) * | 2022-05-13 | 2023-11-16 | Tiziana Life Sciences Plc | Nasal formulations of foralumab |
| US20260055193A1 (en) * | 2022-07-27 | 2026-02-26 | Celldex Therapeutics, Inc. | Anti-kit antibody formulations and methods |
| US20250381184A1 (en) | 2022-09-09 | 2025-12-18 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising an anti-cd3 antibody and a cxcr3 antagonist |
| CN121002056A (zh) | 2023-02-08 | 2025-11-21 | 免疫标记治疗股份公司 | β2微球蛋白、HLA重链多肽、和CD47–SIRPα抑制剂的融合蛋白 |
| WO2024182767A1 (en) | 2023-03-01 | 2024-09-06 | Provention Bio, Inc. | Methods and compositions for treating type 1 diabetes comprising teplizumab and verapamil |
| KR20250156121A (ko) | 2023-03-16 | 2025-10-31 | 오노 야꾸힝 고교 가부시키가이샤 | 항체 제제 |
| WO2024190892A1 (ja) | 2023-03-16 | 2024-09-19 | 小野薬品工業株式会社 | 抗体製剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030235583A1 (en) | 2002-06-14 | 2003-12-25 | Jeppe Sturis | Combined use of a modulator of CD3 and a beta cell resting compound |
| US20040037826A1 (en) | 2002-06-14 | 2004-02-26 | Michelsen Birgitte Koch | Combined use of a modulator of CD3 and a GLP-1 compound |
| US7883703B2 (en) * | 2003-11-14 | 2011-02-08 | The Brigham And Women's Hospital, Inc. | Methods of modulating immunity |
| CN101309703A (zh) | 2005-09-12 | 2008-11-19 | 诺维莫尼公司 | 抗cd3抗体组合物 |
| CA2638811A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2009070642A1 (en) | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
| CN102164960A (zh) * | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
| JP2012530721A (ja) | 2009-06-18 | 2012-12-06 | ワイス・エルエルシー | 小モジュール免疫薬のための凍結乾燥製剤 |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| CA2778334A1 (en) * | 2009-10-20 | 2011-04-28 | Charlotte Mckee | Anti-cd3 antibody dosing in autoimmune disease |
| CA2778331A1 (en) * | 2009-10-20 | 2011-04-28 | Aoife Brennan | Methods of using anti-cd3 antibodies to prevent weight gain |
| BR112012013148A2 (pt) | 2009-12-29 | 2017-03-21 | F Hoffmann - La Roche Ag | formulação farmacêutica e uso |
| WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
| CN116617387A (zh) | 2016-08-29 | 2023-08-22 | 迪赞纳生命科学公开有限公司 | 抗cd3抗体制剂 |
-
2017
- 2017-08-29 CN CN202211674110.7A patent/CN116617387A/zh active Pending
- 2017-08-29 CN CN201780052970.8A patent/CN109843920B/zh active Active
- 2017-08-29 CA CA3032596A patent/CA3032596A1/en active Pending
- 2017-08-29 JP JP2019531579A patent/JP7057360B2/ja active Active
- 2017-08-29 US US15/690,192 patent/US10688186B2/en active Active
- 2017-08-29 EP EP17765519.8A patent/EP3504241B1/en active Active
- 2017-08-29 AU AU2017319318A patent/AU2017319318B2/en active Active
- 2017-08-29 WO PCT/US2017/049211 patent/WO2018044948A1/en not_active Ceased
- 2017-08-29 EP EP24175798.8A patent/EP4406554A3/en active Pending
- 2017-08-29 IL IL264502A patent/IL264502B2/en unknown
- 2017-08-29 DK DK17765519.8T patent/DK3504241T3/da active
- 2017-08-29 IL IL301948A patent/IL301948B2/en unknown
- 2017-08-29 ES ES17765519T patent/ES2986900T3/es active Active
-
2020
- 2020-05-18 US US16/876,839 patent/US20210000957A1/en not_active Abandoned
-
2022
- 2022-04-07 JP JP2022063973A patent/JP7461401B2/ja active Active
-
2024
- 2024-03-22 JP JP2024046063A patent/JP2024075713A/ja active Pending
- 2024-12-16 AU AU2024278457A patent/AU2024278457A1/en active Pending
-
2025
- 2025-02-07 US US19/048,132 patent/US20250228946A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024075713A5 (https=) | ||
| JP2023515271A5 (https=) | ||
| JP2022105138A5 (https=) | ||
| JP2021517566A5 (https=) | ||
| JP2021526534A5 (https=) | ||
| US20110256130A1 (en) | Methods of treating inflammatory disorders | |
| US20010018053A1 (en) | Methods for treating disease states comprising administration of low levels of antibodies | |
| JP6554155B2 (ja) | Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法 | |
| JP2014114288A5 (https=) | ||
| JP2012505160A (ja) | 炎症を処置する方法 | |
| JP2020128375A (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| JP2025032102A5 (https=) | ||
| JP2017160178A5 (https=) | ||
| JP2023528265A5 (https=) | ||
| JP2025128343A5 (https=) | ||
| JP2022523530A5 (https=) | ||
| JP2022512704A5 (https=) | ||
| JP2021511024A5 (https=) | ||
| JP2023518066A5 (https=) | ||
| WO2018015880A1 (en) | Methods of treating new-onset plaque type psoriasis using il-17 antagonists | |
| JP2018529661A5 (https=) | ||
| JP2025069284A5 (https=) | ||
| JP2019519584A5 (https=) | ||
| CN115697378A (zh) | 用cgrp抑制剂治疗肺部损伤的方法 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 |